DNA Script, a Paris, France-based biotechnology company focused on Enzymatic DNA Synthesis (EDS) and DNA printing on demand, raised $165M in Series C funding.
The round, which brought the total amount raised to date by to $280m was led by Coatue Management and Catalio Capital Management with participation from Fidelity Management and Research, Columbia Threadneedle Investments, Arrowmark Partners, Farallon Capital and Moore Strategic Ventures, Casdin Capital, LSP, Illumina Ventures, Bpifrance Large Venture Fund, Danaher Life Sciences, Agilent Technologies, M Ventures, Kurma Partners and Alexandria Venture Investment.
The company intends to use the funds to accelerate expansion and commercialization of its Syntax Platform and broaden the portfolio of products powered by EDS.
Led by Thomas Ybert, CEO, DNA Script provides a way to design and manufacture nucleic acids. The company has developed an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, allowing this technology to be accessible to labs with a benchtop enzymatic synthesis instrument, the Syntax System.
The company announced last June the targeted release of the SYNTAX System, a benchtop instrument along with software, and reagent kits. The platform provides in-house DNA printing – without using toxic organic chemicals or extended delivery wait times from third-party DNA service providers – for labs of all sizes. The automated instrument sets up in 15 minutes and within a few hours produces up to 96 oligos immediately ready for use in genomics and molecular biology research.